ProPhase Labs, Inc. (PRPH)

ProPhase Labs' stock price has significantly declined over the past six months. Key events impacting the stock include a decrease in Q3 2025 revenue, a proposed reverse merger with Advanced Biological Laboratories (ABL S.A.), uplisting to the OTC market, convertible debt conversions, initiation of a potential sale or strategic partnership process for its BE-Smart™ esophageal cancer test, advancement of its Crown Medical Collections initiative, Q2 2025 financial results, and the Chapter 11 filing by its COVID-19 lab testing units.

ProPhase Labs experiences demand seasonality, particularly within its consumer products segment, with seasonally low revenue for Pharmaloz. To mitigate this, ProPhase Labs is implementing price increases and seeking year-round lozenge brands. Diagnostic services related to infectious diseases also likely experience seasonality based on disease prevalence.

ProPhase Labs, Inc. is a medical science and technology company focused on developing, manufacturing, and commercializing health and wellness solutions. It operates through Diagnostic Services, including the BE-Smart™ Esophageal Pre-Cancer diagnostics screening test and genomics testing via Nebula Genomics, and Consumer Products, featuring OTC healthcare products and dietary supplements under the TK Supplements® brand, along with contract manufacturing through Pharmaloz Manufacturing, Inc. The company is categorized within the Health Technology sector and the Pharmaceuticals: Other or Diagnostics & Research industry and was founded in 1989, with its headquarters in Garden City, New York.

ProPhase Labs, Inc. primarily operates within the United States, where its diagnostic services are provided to health plans, third-party payers, and government organizations, and its consumer products are developed, manufactured, distributed, marketed, and sold. While its Nebula Genomics subsidiary operates one of the largest and most diverse genomic datasets globally, spanning 130 countries, the company's core operational footprint for its services and product sales is concentrated in the U.S.

ProPhase Labs' brand reputation has been influenced by positive developments and challenges. Positive events include validation and commercialization efforts for BE-Smart™, streamlining of Nebula Genomics, and the Crown Medical Collections Initiative. However, the significant decline in stock price, the move from Nasdaq to the OTC market, and the revenue decrease in Q3 2025 could negatively impact investor confidence and public perception.

The ownership structure of ProPhase Labs (PRPH) stock includes institutional, retail, and individual investors. Approximately 14.00% of the company's stock is owned by Institutional Investors, 64.06% by Insiders, and 21.94% by Public Companies and Individual Investors. Ted William Karkus, the Chairman and Chief Executive Officer, is a significant individual shareholder.